Home › Funds › DAFNA Capital Management LLC › RNA

DAFNA Capital Management LLC position in RNA

ATRIUM THERAPEUTICS INC · Health Care

DAFNA Capital Management LLC reported holding 300,076 shares of RNA (ATRIUM THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$2.5M, representing 0.53% of its reported portfolio and ranking #38 among its reported holdings. DAFNA Capital Management LLC has disclosed RNA holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

Latest position (Q3 2026)300.08K sh
Reported value held$2.48M
Portfolio Weight0.53%
First reportedQ2 2026
Last changeAdd
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How DAFNA Capital Management LLC's RNA position evolved

DAFNA Capital Management LLC first disclosed a stake in RNA in Q2 2026 at 128,000 shares (US$1.7M). The position peaked in Q3 2026 at 300,076 shares, worth US$2.5M. Across 2 filings, DAFNA Capital Management LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 300,076 shares valued at US$2.5M — an increase of 172,076 shares quarter over quarter.. Notable position changes include a 134% increase in Q3 2026 (shares fell 22% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2026 128.00K $1.72M New
Q3 2026 300.08K $2.48M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RNA and 13F data

RNA (ATRIUM THERAPEUTICS INC) is a Health Care company. 79 other funds we track also report a position in RNA — the largest reported positions include Sessa Capital IM, L.P. (US$12.4M), O'Connor Alternative Investments LLC (US$4.6M), Bracebridge Capital, LLC (US$4.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RNA

All RNA fund holders →

FAQ

How long has DAFNA Capital Management LLC held RNA?

DAFNA Capital Management LLC has disclosed RNA holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

What is DAFNA Capital Management LLC's current position in RNA?

As of Q3 2026, DAFNA Capital Management LLC holds 300.08K shares of RNA (ATRIUM THERAPEUTICS INC), valued at $2.48M, representing 0.53% of its reported portfolio and ranking #38.

Has DAFNA Capital Management LLC been buying or selling RNA?

In the latest 13F filing (Q3 2026), DAFNA Capital Management LLC increased its position in RNA. The position peaked in Q3 2026 at 300.08K shares.

Which other funds hold RNA?

Other major institutional holders of RNA include Sessa Capital IM, L.P., O'Connor Alternative Investments LLC, Bracebridge Capital, LLC, among 79 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.